Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamadermatol.2015.5210 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors.
Immunother Adv
September 2022
Dermatology Department, Harvard Medical School, Boston, MA, USA.
Background: Cutaneous immune-related adverse events (irAEs) are the most common irAEs caused by immune-checkpoint inhibitors (ICI). Psoriasiform eruptions, both and flares, may occur. Evidence is lacking on inverse psoriasis subtype.
View Article and Find Full Text PDFHistopathologic features of inverse psoriasis.
J Cutan Pathol
March 2022
Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois, USA.
Background: Inverse psoriasis represents a less commonly described form of psoriasis in intertriginous areas. The pathologic findings of inverse psoriasis are typically grouped in with those of plaque psoriasis, as the histopathologic features specific to inverse psoriasis have not received significant investigation.
Methods: A single institution, retrospective cohort study was performed to review biopsy slides for psoriasis occurring in typical intertriginous areas.
IL-23 induces regulatory T cell plasticity with implications for inflammatory skin diseases.
Sci Rep
November 2019
Abbvie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.
Foxp3 regulatory T cells (Tregs) represent a major fraction of skin resident T cells. Although normally protective, Tregs have been shown to produce pro-inflammatory cytokines in human diseases, including psoriasis. A significant hurdle in the Treg field has been the identification, or development, of model systems to study this Treg plasticity.
View Article and Find Full Text PDFInhibition of Interleukin-23-Mediated Inflammation with a Novel Small Molecule Inverse Agonist of RORt.
J Pharmacol Exp Ther
October 2019
AbbVie Inc., North Chicago, Illinois (S.B.G., Y.W., L.L., S.H., Z.S., J.W., K.S., S.P.M., P.H., K.D., M.E.K., D.G., R.E.); Inventiva, Daix, France (J.-M.L., D.B., D.P., P.J.M., S.J.); and AbbVie Bioresearch Center, Worcester, Massachusetts (C.W., R.M., C.G., M.A.A., E.B., K.C.).
Blockade of interleukin (IL)-23 or IL-17 with biologics is clinically validated as a treatment of psoriasis. However, the clinical impact of targeting other nodes within the IL-23/IL-17 pathway, especially with small molecules, is less defined. We report on a novel small molecule inverse agonist of retinoid acid-related orphan receptor (ROR) t and its efficacy in preclinical models of psoriasis and arthritis.
View Article and Find Full Text PDFThe non-neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond.
Br J Dermatol
May 2018
Department of Dermatology, University of California, Irvine, Irvine, CA, U.S.A.
There is growing evidence that botulinum neurotoxins (BoNTs) exhibit biological effects on various human cell types with a host of associated clinical implications. This review aims to provide an update on the non-neuronal and nonmuscular effects of botulinum toxin. We critically analysed recent reports on the structure and function of cellular signalling systems subserving biological effects of BoNTs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!